Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genes
ConclusionIn summary, 4 m6A related- ERGs were identified and the corresponding prognostic model was constructed for AML patients. This prognostic model effectively stratified the risk of AML patients. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - November 22, 2023 Category: Allergy & Immunology Source Type: research
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. This analysis a... (Source: BMC Cancer)
Source: BMC Cancer - November 21, 2023 Category: Cancer & Oncology Authors: Joseph Kauer, Emma P. Freundt, Anita Schmitt, Niels Weinhold, Elias K. Mai, Carsten M üller-Tidow, Hartmut Goldschmidt, Marc S. Raab, Katharina Kriegsmann and Sandra Sauer Tags: Research Source Type: research
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma
Haematologica. 2023 Nov 16. doi: 10.3324/haematol.2023.283787. Online ahead of print.ABSTRACTMultiple myeloma (MM) is a malignancy of plasma cells whose antibody secretion creates proteotoxic stress relieved by the N-end rule pathway, a proteolytic system that degrades Narginylated proteins in the proteasome. When the proteasome is inhibited, protein cargo is alternatively targeted for autophagic degradation by binding to the ZZ-domain of p62/sequestosome-1. Here, we demonstrate that XRK3F2, a selective ligand for the ZZ-domain, dramatically improved two major responses to the proteasome inhibitor bortezomib by increasing:...
Source: Haematologica - November 20, 2023 Category: Hematology Authors: Silvia Marino Daniela N Petrusca Ryan T Bishop Judith L Anderson Hayley M Sabol Cody Ashby Justin H Layer Annamaria Cesarano Utpal P Dav é Fabiana Perna Jesus Delgado-Calle John M Chirgwin G David Roodman Source Type: research
Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China
CONCLUSION: The results of our study showed that a large proportion of Chinese hematologists failed to recognize the VTE risk factors, most of them cannot select appropriate thromboprophylaxis for different MM therapeutic regimens and lack awareness of stratified thromboprophylaxis for MM-associated VTE. A standard VTE prevention guideline is urgently needed for the Chinese myeloma group. Continuous education for new professionals should be encouraged. A VTE collaborative group is supposed to be established in each hospital to enhance the overall medical care for VTE patients.PMID:37983471 | DOI:10.1080/07853890.2023.22630...
Source: Annals of Medicine - November 20, 2023 Category: Internal Medicine Authors: Qun Li Bo Zhang Qianwen Cheng Fei Zhao Junying Li Han Yan Aoshuang Xu Chunyan Sun Yu Hu Source Type: research
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma
Haematologica. 2023 Nov 16. doi: 10.3324/haematol.2023.283787. Online ahead of print.ABSTRACTMultiple myeloma (MM) is a malignancy of plasma cells whose antibody secretion creates proteotoxic stress relieved by the N-end rule pathway, a proteolytic system that degrades Narginylated proteins in the proteasome. When the proteasome is inhibited, protein cargo is alternatively targeted for autophagic degradation by binding to the ZZ-domain of p62/sequestosome-1. Here, we demonstrate that XRK3F2, a selective ligand for the ZZ-domain, dramatically improved two major responses to the proteasome inhibitor bortezomib by increasing:...
Source: Haematologica - November 20, 2023 Category: Hematology Authors: Silvia Marino Daniela N Petrusca Ryan T Bishop Judith L Anderson Hayley M Sabol Cody Ashby Justin H Layer Annamaria Cesarano Utpal P Dav é Fabiana Perna Jesus Delgado-Calle John M Chirgwin G David Roodman Source Type: research
Making decisions for follow-up chemotherapy based on digital patient reported outcomes data in patients with multiple myeloma and other M protein diseases - A mixed method study
CONCLUSION: The use of PRO data to evaluate patients prior to bortezomib treatment is safe and feasible. Patients prefer to report their side effects themselves as it provides them with more freedom during their treatment.PMID:37984313 | DOI:10.1016/j.ejon.2023.102455 (Source: European Journal of Oncology Nursing)
Source: European Journal of Oncology Nursing - November 20, 2023 Category: Nursing Authors: Tine Rosenberg Jannie Kirkegaard Michael Gundesen Tveden Nana Hyldig Karin Brochstedt Dieperink Nanna Hanneberg Steffensen Stine Br øgger Ulriksen Thomas Lund Source Type: research
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma
Haematologica. 2023 Nov 16. doi: 10.3324/haematol.2023.283787. Online ahead of print.ABSTRACTMultiple myeloma (MM) is a malignancy of plasma cells whose antibody secretion creates proteotoxic stress relieved by the N-end rule pathway, a proteolytic system that degrades Narginylated proteins in the proteasome. When the proteasome is inhibited, protein cargo is alternatively targeted for autophagic degradation by binding to the ZZ-domain of p62/sequestosome-1. Here, we demonstrate that XRK3F2, a selective ligand for the ZZ-domain, dramatically improved two major responses to the proteasome inhibitor bortezomib by increasing:...
Source: Haematologica - November 20, 2023 Category: Hematology Authors: Silvia Marino Daniela N Petrusca Ryan T Bishop Judith L Anderson Hayley M Sabol Cody Ashby Justin H Layer Annamaria Cesarano Utpal P Dav é Fabiana Perna Jesus Delgado-Calle John M Chirgwin G David Roodman Source Type: research
5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib
Eur J Med Chem. 2023 Nov 10;263:115907. doi: 10.1016/j.ejmech.2023.115907. Online ahead of print.ABSTRACTClinically used pan and class I HDACi cause severe side effects, whereas class IIa HDACi are less cytotoxic. Here, we present the synthesis and anticancer effects of a series of 5-(trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based amides and alkoxyamides derived from the previously reported class IIa HDACi YAK540. The most active class IIa inhibitor 1a showed nanomolar inhibition of the class IIa enzymes 4, 5, 7 (IC50 HDAC4: 12 nM) and high selectivity (selectivity index >318 for HDAC4) over non-class IIa HDACs. Instead...
Source: European Journal of Medicinal Chemistry - November 18, 2023 Category: Chemistry Authors: Yodita Asfaha Lukas M Bollmann Alexander J Skerhut Fabian Fischer Nadine Horstick Dennis Roth Maria Wecker Christian Mammen Sander H J Smits Georg Fluegen Matthias U Kassack Thomas Kurz Source Type: research
5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib
Eur J Med Chem. 2023 Nov 10;263:115907. doi: 10.1016/j.ejmech.2023.115907. Online ahead of print.ABSTRACTClinically used pan and class I HDACi cause severe side effects, whereas class IIa HDACi are less cytotoxic. Here, we present the synthesis and anticancer effects of a series of 5-(trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based amides and alkoxyamides derived from the previously reported class IIa HDACi YAK540. The most active class IIa inhibitor 1a showed nanomolar inhibition of the class IIa enzymes 4, 5, 7 (IC50 HDAC4: 12 nM) and high selectivity (selectivity index >318 for HDAC4) over non-class IIa HDACs. Instead...
Source: European Journal of Medicinal Chemistry - November 18, 2023 Category: Chemistry Authors: Yodita Asfaha Lukas M Bollmann Alexander J Skerhut Fabian Fischer Nadine Horstick Dennis Roth Maria Wecker Christian Mammen Sander H J Smits Georg Fluegen Matthias U Kassack Thomas Kurz Source Type: research
A novel telomere-related genes model for predicting prognosis and treatment responsiveness in diffuse large B-cell lymphoma
In conclusion, our novel TRGs-based model has great predictive value for the prognosis of DLBCL patients and provides a promising direction for treatment optimization.PMID:37976136 | DOI:10.18632/aging.205211 (Source: Aging)
Source: Aging - November 17, 2023 Category: Biomedical Science Authors: Zhijia Zhao Xiaochen Shen Siqi Zhao Jinhua Wang Yuqin Tian Xiaobo Wang Bo Tang Source Type: research
A novel telomere-related genes model for predicting prognosis and treatment responsiveness in diffuse large B-cell lymphoma
In conclusion, our novel TRGs-based model has great predictive value for the prognosis of DLBCL patients and provides a promising direction for treatment optimization.PMID:37976136 | DOI:10.18632/aging.205211 (Source: Aging)
Source: Aging - November 17, 2023 Category: Biomedical Science Authors: Zhijia Zhao Xiaochen Shen Siqi Zhao Jinhua Wang Yuqin Tian Xiaobo Wang Bo Tang Source Type: research
CTIVA: Censored time interval variable analysis
by Insoo Kim, Junhee Seok, Yoojoong Kim
Traditionally, datasets with multiple censored time-to-events have not been utilized in multivariate analysis because of their high level of complexity. In this paper, we propose the Censored Time Interval Analysis (CTIVA) method to address this issue. It estimates the joint probability distributi on of actual event times in the censored dataset by implementing a statistical probability density estimation technique on the dataset. Based on the acquired event time, CTIVA investigates variables correlated with the interval time of events via statistical tests. The proposed method hand...
Source: PLoS One - November 16, 2023 Category: Biomedical Science Authors: Insoo Kim Source Type: research
The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells
In this study, using a direct in vitro approach, we show that deletion of the tumor suppressor and cell cycle regulator p53 rescues recently activated mouse B cells from BTZ-induced apoptosis. Furthermore, BTZ treatment elevated intracellular p53 levels, and p53 deletion constrained apoptosis, as recently stimulated cells first transitioned from the G1 to S phase of the cell cycle. Moreover, combined inhibition of the p53-associated cell cycle regulators and E3 ligases MDM2 and anaphase-promoting complex/cyclosome induced cell death in postdivision B cells. Our results reveal that efficient cell cycle progression of activa...
Source: Journal of Immunology - November 15, 2023 Category: Allergy & Immunology Authors: Trini A Ochoa Amy Rossi E Steve Woodle David Hildeman David Allman Source Type: research
The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells
In this study, using a direct in vitro approach, we show that deletion of the tumor suppressor and cell cycle regulator p53 rescues recently activated mouse B cells from BTZ-induced apoptosis. Furthermore, BTZ treatment elevated intracellular p53 levels, and p53 deletion constrained apoptosis, as recently stimulated cells first transitioned from the G1 to S phase of the cell cycle. Moreover, combined inhibition of the p53-associated cell cycle regulators and E3 ligases MDM2 and anaphase-promoting complex/cyclosome induced cell death in postdivision B cells. Our results reveal that efficient cell cycle progression of activa...
Source: Journal of Immunology - November 15, 2023 Category: Allergy & Immunology Authors: Trini A Ochoa Amy Rossi E Steve Woodle David Hildeman David Allman Source Type: research
The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells
In this study, using a direct in vitro approach, we show that deletion of the tumor suppressor and cell cycle regulator p53 rescues recently activated mouse B cells from BTZ-induced apoptosis. Furthermore, BTZ treatment elevated intracellular p53 levels, and p53 deletion constrained apoptosis, as recently stimulated cells first transitioned from the G1 to S phase of the cell cycle. Moreover, combined inhibition of the p53-associated cell cycle regulators and E3 ligases MDM2 and anaphase-promoting complex/cyclosome induced cell death in postdivision B cells. Our results reveal that efficient cell cycle progression of activa...
Source: Journal of Immunology - November 15, 2023 Category: Allergy & Immunology Authors: Trini A Ochoa Amy Rossi E Steve Woodle David Hildeman David Allman Source Type: research
